Literatur
James RD et al. Lancet Oncol. 2013;14(6):516–24.
Garg MK et al. J Clin Oncol. 2017;35(7):718–726.
Gunderson LL et al. J Clin Oncol. 2012;30(35):4344–51.
Glynne-Jones R et al. Lancet Oncol. 2017;18(3):347–356.
Doll CM et al. Int J Radiat Oncol Biol Phys. 2017;97(3):554–562.
Yates A et al. Clin Oncol (R Coll Radiol). 2015;27(12):700–7.
Originalie
Garg MK. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol. 2017;35(7):718–26.
Author information
Authors and Affiliations
Corresponding author
Additional information
Erstpubliziert in Strahlenther Onkol. 2017;193(6):508-9.
Rights and permissions
About this article
Cite this article
Nieder, C. Addition von Cetuximab zur Radiochemotherapie von Analkarzinomen. Info Onkol. 20, 16–17 (2017). https://doi.org/10.1007/s15004-017-5843-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-017-5843-0